V. Özmen, B. Çakar, E. Gökmen, M. Özdoğan, N. Güler, C. Uras, E. Ok, O. Demircan, A. Işıkdoğan, P. Saip
Objective Breast cancer is a heterogenous disease, and genetic profiling helps to individualize adjuvant treatment. The Oncotype DX is a validated test to predict benefit of adjuvant systemic treatment. The aims of this study are to determine the costs of chemotherapy in government hospitals in Turkey and evaluate the cost-effectiveness of the Oncotype DX from the national insurance perspective. Materials and Methods A Markov model was developed to make long term projections of distant recurrence, survival, quality adjusted life expectancy, and direct costs for patients with ER+, HER2-, node-negative or up to 3 node-positive early stage breast cancer. Turkish decision impact study patient data were captured for model reference. In that study, ten academic centers across Turkey participated in a prospective trial. Of 165 patients with pT1-3, pN0-N1mic, ER-positive, and HER-2 negative tumors, 57% had low recurrence score (RS), 35% had intermediate RS, and 8% had high RS, respectively. The overall rate of change in chemotherapy treatment decisions following Oncotype DX was 33%. Results The cost of adjuvant chemotherapy in public hospitals was estimated at $3.649, and Oncotype Dx test was $5.141. Based on the cost-effectiveness analysis, Oncotype DX testing was estimated to improve life expectancy (+0.86 years) and quality-adjusted life expectancy (+0.68 QALYs) versus standard care. The incremental cost-effectiveness ratio (ICERs) of Oncotype DX was estimated to be $7207.9 per QALY gained and $5720.6 per LY gained versus current clinical practice. Conclusion As Oncotype DX was found both cost-effective and life-saving from a national perspective, the test should be introduced to standard care in patients with ER+, HER-2 negative early-stage breast cancer in Turkey.
{"title":"Cost effectiveness of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in a Middle-Income Country, Turkey: Results of a Prospective Multicenter Study.","authors":"V. Özmen, B. Çakar, E. Gökmen, M. Özdoğan, N. Güler, C. Uras, E. Ok, O. Demircan, A. Işıkdoğan, P. Saip","doi":"10.5152/ejbh.2019.4761","DOIUrl":"https://doi.org/10.5152/ejbh.2019.4761","url":null,"abstract":"Objective\u0000Breast cancer is a heterogenous disease, and genetic profiling helps to individualize adjuvant treatment. The Oncotype DX is a validated test to predict benefit of adjuvant systemic treatment. The aims of this study are to determine the costs of chemotherapy in government hospitals in Turkey and evaluate the cost-effectiveness of the Oncotype DX from the national insurance perspective.\u0000\u0000\u0000Materials and Methods\u0000A Markov model was developed to make long term projections of distant recurrence, survival, quality adjusted life expectancy, and direct costs for patients with ER+, HER2-, node-negative or up to 3 node-positive early stage breast cancer. Turkish decision impact study patient data were captured for model reference. In that study, ten academic centers across Turkey participated in a prospective trial. Of 165 patients with pT1-3, pN0-N1mic, ER-positive, and HER-2 negative tumors, 57% had low recurrence score (RS), 35% had intermediate RS, and 8% had high RS, respectively. The overall rate of change in chemotherapy treatment decisions following Oncotype DX was 33%.\u0000\u0000\u0000Results\u0000The cost of adjuvant chemotherapy in public hospitals was estimated at $3.649, and Oncotype Dx test was $5.141. Based on the cost-effectiveness analysis, Oncotype DX testing was estimated to improve life expectancy (+0.86 years) and quality-adjusted life expectancy (+0.68 QALYs) versus standard care. The incremental cost-effectiveness ratio (ICERs) of Oncotype DX was estimated to be $7207.9 per QALY gained and $5720.6 per LY gained versus current clinical practice.\u0000\u0000\u0000Conclusion\u0000As Oncotype DX was found both cost-effective and life-saving from a national perspective, the test should be introduced to standard care in patients with ER+, HER-2 negative early-stage breast cancer in Turkey.","PeriodicalId":91975,"journal":{"name":"The journal of breast health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42285616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Childhood breast masses are mostly benign conditions starting from the newborn period continuing on to adolescence yet can cause high anxiety in the child and the family as well. As a complaint or physical finding, usually palpable mass, pain or discharge from the nipple is apparent in patients. All the clinicians interested in pediatric field should have full knowledge of immature and developing breasts so to proper diagnose and avoid overtreatment with unnecessary diagnostic or surgical procedures. Though malignancy or life-threatening disease has a very low probability during childhood, all child patients should be evaluated and followed up carefully. Especially training and then encouraging young people to periodically start self-assessment of the breasts after their 19th birthday while warning the ones who have had therapeutic chest radiation previously to begin self-assessment 8 years after the procedure or at 25 years of age whichever comes last, will be an appropriate intervention.
{"title":"Clinical Evaluation of Breast in Childhood.","authors":"Selda Karaayvaz","doi":"10.5152/ejbh.2019.4745","DOIUrl":"https://doi.org/10.5152/ejbh.2019.4745","url":null,"abstract":"Childhood breast masses are mostly benign conditions starting from the newborn period continuing on to adolescence yet can cause high anxiety in the child and the family as well. As a complaint or physical finding, usually palpable mass, pain or discharge from the nipple is apparent in patients. All the clinicians interested in pediatric field should have full knowledge of immature and developing breasts so to proper diagnose and avoid overtreatment with unnecessary diagnostic or surgical procedures. Though malignancy or life-threatening disease has a very low probability during childhood, all child patients should be evaluated and followed up carefully. Especially training and then encouraging young people to periodically start self-assessment of the breasts after their 19th birthday while warning the ones who have had therapeutic chest radiation previously to begin self-assessment 8 years after the procedure or at 25 years of age whichever comes last, will be an appropriate intervention.","PeriodicalId":91975,"journal":{"name":"The journal of breast health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48104859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Zeliha Türkyılmaz, Tahacan Aydın, R. Yılmaz, Semen Önder, E. Özkurt, M. Tükenmez, M. Müslümanoğlu, G. Acunaş, A. Igci, V. Özmen, A. Dinçağ, N. Cabioğlu
Objective Hamartomas are rare, slowly-growing breast tumours. Clinical, radiological and histopathological examination together increase the diagnostic accuracy. To evaluate the clinicopathologic features of hamartomas and outline our clinical approach to hamartomas in our 20-year experience at our Breast Clinic. Materials and Methods Between 1995 and 2015, 24 cases were retrospectively analyzed with a diagnosis of breast hamartoma at our Breast Clinic followed by excisional biopsy. Data was obtained on patient demographics, clinical examination, radiological findings and histopathological subtypes. Results Of 1338 benign breast tumours excised from January 1995 to January 2015, 24 (1.8%) were identified as breast hamartoma. Median age of patients was 42 (range, 13-70), whereas the median tumour size was 5 cm (1-10 cm). On preoperative imaging, hamartoma was most commonly misdiagnosed as fibroadenoma. Pathological examination of the 24 biopsy specimens revealed 3 cases with pseudoangiomatous stromal hyperplasia, and another hamartoma associated with a radial scar within the centre of the lesion. Of those, one patient was diagnosed with malignant phylloides tumour in the same breast. At a median follow-up 58.4 months, none of the patients recurred or developed malignancy. Conclusion Hamartomas can often be missed by clinicians, due to its benign nature which is poorly understood. Despite their slow growth, hamartomas can reach large sizes and can cause breast asymmetry. Although it is rare, hamartoma can be seen along with malignancy, as it is formed from similar components of breast tissue. Therefore, careful diagnosis and appropriate management including surgery are required.
{"title":"Our 20-Year Institutional Experience with Surgical Approach for Breast Hamartomas.","authors":"Zeliha Türkyılmaz, Tahacan Aydın, R. Yılmaz, Semen Önder, E. Özkurt, M. Tükenmez, M. Müslümanoğlu, G. Acunaş, A. Igci, V. Özmen, A. Dinçağ, N. Cabioğlu","doi":"10.5152/ejbh.2019.4624","DOIUrl":"https://doi.org/10.5152/ejbh.2019.4624","url":null,"abstract":"Objective\u0000Hamartomas are rare, slowly-growing breast tumours. Clinical, radiological and histopathological examination together increase the diagnostic accuracy. To evaluate the clinicopathologic features of hamartomas and outline our clinical approach to hamartomas in our 20-year experience at our Breast Clinic.\u0000\u0000\u0000Materials and Methods\u0000Between 1995 and 2015, 24 cases were retrospectively analyzed with a diagnosis of breast hamartoma at our Breast Clinic followed by excisional biopsy. Data was obtained on patient demographics, clinical examination, radiological findings and histopathological subtypes.\u0000\u0000\u0000Results\u0000Of 1338 benign breast tumours excised from January 1995 to January 2015, 24 (1.8%) were identified as breast hamartoma. Median age of patients was 42 (range, 13-70), whereas the median tumour size was 5 cm (1-10 cm). On preoperative imaging, hamartoma was most commonly misdiagnosed as fibroadenoma. Pathological examination of the 24 biopsy specimens revealed 3 cases with pseudoangiomatous stromal hyperplasia, and another hamartoma associated with a radial scar within the centre of the lesion. Of those, one patient was diagnosed with malignant phylloides tumour in the same breast. At a median follow-up 58.4 months, none of the patients recurred or developed malignancy.\u0000\u0000\u0000Conclusion\u0000Hamartomas can often be missed by clinicians, due to its benign nature which is poorly understood. Despite their slow growth, hamartomas can reach large sizes and can cause breast asymmetry. Although it is rare, hamartoma can be seen along with malignancy, as it is formed from similar components of breast tissue. Therefore, careful diagnosis and appropriate management including surgery are required.","PeriodicalId":91975,"journal":{"name":"The journal of breast health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42339362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Lapatinib? or Radiotherapy? In Cranial Metastasis of Breast Cancer.","authors":"Y. Cihan","doi":"10.5152/ejbh.2019.4874","DOIUrl":"https://doi.org/10.5152/ejbh.2019.4874","url":null,"abstract":"","PeriodicalId":91975,"journal":{"name":"The journal of breast health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44464911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
in the treatment area and the complications that may occur. It has been reported that silicone breast prostheses have no negative effect on photon and electron dose distribution. In addition, it was determined that the silicone elastomer used in breast prostheses did not reduce the radiation transmission (9). There is not enough information in the literature regarding the prevention / treatment of complications in prostheses after RT. In studies performed, it was shown that complications of complications such as capsular contracture (1.3-15%) and worse cosmetic results and reconstruction after radiotherapy treatment have increased in patients with breast reconstruction with silicone implant (2, 3, 6-8). However, most of the current studies are retrospective cohort studies and there is no prospective study. The effects of radiation on the formation of capsules are tried to be explained. Recent studies have shown that the transforming growth factor- β (TGF- β 1) is an important factor in the formation of fibrosis and radiation-induced capsule formation. Positive results have been reported in studies to prevent these effects by inhibition of TGF- β signal transduction (3). Evans et al. (4) performed breast reconstruction with implants and compared the contracture stage, pain and extrusion in patients with RT without RT. They reported that radiotherapy increased the capsular contracture stage (Baker III, IV) and had significant negative consequences for the clinical appearance and patient satisfaction. Azzi et al. (5) reported that radiotherapy accelerated the process of capsular contracture around the silicone implant in a study of 105 patients.
{"title":"Treatment of Capsular Contracture After Radiotherapy in Breast Reconstruction.","authors":"Y. Cihan, H. Baykan, A. Arslan","doi":"10.5152/ejbh.2019.4713","DOIUrl":"https://doi.org/10.5152/ejbh.2019.4713","url":null,"abstract":"in the treatment area and the complications that may occur. It has been reported that silicone breast prostheses have no negative effect on photon and electron dose distribution. In addition, it was determined that the silicone elastomer used in breast prostheses did not reduce the radiation transmission (9). There is not enough information in the literature regarding the prevention / treatment of complications in prostheses after RT. In studies performed, it was shown that complications of complications such as capsular contracture (1.3-15%) and worse cosmetic results and reconstruction after radiotherapy treatment have increased in patients with breast reconstruction with silicone implant (2, 3, 6-8). However, most of the current studies are retrospective cohort studies and there is no prospective study. The effects of radiation on the formation of capsules are tried to be explained. Recent studies have shown that the transforming growth factor- β (TGF- β 1) is an important factor in the formation of fibrosis and radiation-induced capsule formation. Positive results have been reported in studies to prevent these effects by inhibition of TGF- β signal transduction (3). Evans et al. (4) performed breast reconstruction with implants and compared the contracture stage, pain and extrusion in patients with RT without RT. They reported that radiotherapy increased the capsular contracture stage (Baker III, IV) and had significant negative consequences for the clinical appearance and patient satisfaction. Azzi et al. (5) reported that radiotherapy accelerated the process of capsular contracture around the silicone implant in a study of 105 patients.","PeriodicalId":91975,"journal":{"name":"The journal of breast health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46640466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
G. Durhan, Ömer Önder, A. Azizova, J. Karakaya, K. Kösemehmetoğlu, M. Akpınar, F. Demirkazık
Objective Benign fibroepithelial lesions (BFL) lesions of the breast are various and predominantly benign, although a few can be locally aggressive. Definitive diagnosis of some BFL can be challenging from core needle biopsy (CNB). Radiological findings can help guide the management of the lesions. The aim of this study was to investigate the accuracy rate of CNB results and evaluate the radiological findings of the most common BFL according to the final excision pathology results. The secondary aim was to assess the contribution of the imaging findings to CNB results. Materials and Methods A retrospective review was made of 266 patients diagnosed with suspicious BFL, conventional fibroadenoma, complex fibroadenoma, cellular fibroadenoma and benign phyllodes tumor (PT). The study included 132 patients who underwent surgical excision. The radiological and histopathological findings were evaluated. Results While 66 patients were diagnosed with more descriptive results on CNB, the other 66 patients were diagnosed with suspicious BFL. Agreement between CNB and excisional pathology was good, when CNB provided a definite diagnosis. While conventional and complex fibroadenoma were observed to have hypo or normal vascularity, cellular fibroadenoma and PT showed hypervascularity. Oval shaped and homogeneous internal echo pattern were significantly associated with conventional fibroadenoma. A heterogeneous internal echo pattern was seen in complex fibroadenomas and PT. Conclusion CNB often reaches the correct diagnosis alone when it gives a definite diagnosis. The radiological findings which help in the differentiation of BFL are hypervascularity, oval shape and internal heterogeneity. More accurate results can be obtained when histopathological and radiological findings are evaluated together.
{"title":"Can Radiologist and Pathologist Reach The Truth Together in The Diagnosis of Benign Fibroepithelial Lesions?","authors":"G. Durhan, Ömer Önder, A. Azizova, J. Karakaya, K. Kösemehmetoğlu, M. Akpınar, F. Demirkazık","doi":"10.5152/ejbh.2019.4656","DOIUrl":"https://doi.org/10.5152/ejbh.2019.4656","url":null,"abstract":"Objective\u0000Benign fibroepithelial lesions (BFL) lesions of the breast are various and predominantly benign, although a few can be locally aggressive. Definitive diagnosis of some BFL can be challenging from core needle biopsy (CNB). Radiological findings can help guide the management of the lesions. The aim of this study was to investigate the accuracy rate of CNB results and evaluate the radiological findings of the most common BFL according to the final excision pathology results. The secondary aim was to assess the contribution of the imaging findings to CNB results.\u0000\u0000\u0000Materials and Methods\u0000A retrospective review was made of 266 patients diagnosed with suspicious BFL, conventional fibroadenoma, complex fibroadenoma, cellular fibroadenoma and benign phyllodes tumor (PT). The study included 132 patients who underwent surgical excision. The radiological and histopathological findings were evaluated.\u0000\u0000\u0000Results\u0000While 66 patients were diagnosed with more descriptive results on CNB, the other 66 patients were diagnosed with suspicious BFL. Agreement between CNB and excisional pathology was good, when CNB provided a definite diagnosis. While conventional and complex fibroadenoma were observed to have hypo or normal vascularity, cellular fibroadenoma and PT showed hypervascularity. Oval shaped and homogeneous internal echo pattern were significantly associated with conventional fibroadenoma. A heterogeneous internal echo pattern was seen in complex fibroadenomas and PT.\u0000\u0000\u0000Conclusion\u0000CNB often reaches the correct diagnosis alone when it gives a definite diagnosis. The radiological findings which help in the differentiation of BFL are hypervascularity, oval shape and internal heterogeneity. More accurate results can be obtained when histopathological and radiological findings are evaluated together.","PeriodicalId":91975,"journal":{"name":"The journal of breast health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45653607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gozde Arslan, C. Yılmaz, L. Çelik, R. Çubuk, N. Tasalı
We present a case with imaging artefacts on mammography and Magnetic Resonance Imaging (MRI) caused by iron oxide particles. After being diagnosed with the medullary cancer of the breast, the female patient had a breast conserving surgery on right breast. Iron oxide particles were used for the detection of the sentinel lymph node during operation. On follow ups, a de novo density on mammography, which was initially thought to be a new tumour, was found. MR images proved that the lesion is an artefact caused by iron oxide accumulation. Our aim in this case study is to underline and discuss the imaging artefacts caused by these particles and raise awareness.
{"title":"Unexpected Finding on Mammography and MRI due to Accumulation of Iron Oxide Particles Used for Sentinel Lymph Node Detection.","authors":"Gozde Arslan, C. Yılmaz, L. Çelik, R. Çubuk, N. Tasalı","doi":"10.5152/EJBH.2019.4410","DOIUrl":"https://doi.org/10.5152/EJBH.2019.4410","url":null,"abstract":"We present a case with imaging artefacts on mammography and Magnetic Resonance Imaging (MRI) caused by iron oxide particles. After being diagnosed with the medullary cancer of the breast, the female patient had a breast conserving surgery on right breast. Iron oxide particles were used for the detection of the sentinel lymph node during operation. On follow ups, a de novo density on mammography, which was initially thought to be a new tumour, was found. MR images proved that the lesion is an artefact caused by iron oxide accumulation. Our aim in this case study is to underline and discuss the imaging artefacts caused by these particles and raise awareness.","PeriodicalId":91975,"journal":{"name":"The journal of breast health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43301652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective Breast cancer is the most common type of cancer and the leading cause of cancer-related deaths in women in Turkey. This study presents the characteristics of patients registered in National Breast Cancer Registry Program of Turkish Federation of Breast Diseases Societies. Materials and Methods The registry contains 242 variables under 10 categories and 699 questions. Patients were recorded (online and offline) from nationwide breast centers around Turkey. Results Twenty-thousand patients were registered between May 2005 and April 2017 at 36 centers. After data cleaning, 19,503 women were included in the study. The median age at diagnosis was 51 [14-97]; 17.2% were younger than 40 and 37.2% were premenopausal; 13.6% were nulliparous. Breast conserving surgery rate was 39.3%. Histopathology was invasive ductal cancer in 77%. Majority of patients had stage II cancer (48.3%). Estrogen, progesterone and HER-2 receptor positivity rates in invasive breast cancer were 72.5%, 62.5% and 21.8%, respectively. The mean tumor diameter was 2.5±1.7 cm. During the mean 51.6 months of follow-up, the local/regional and systemic recurrence rates were 3.7% and 5.2%, respectively; five and 10-year overall survival rates were 86% and 76%. Conclusion Despite increasing number of screening centers and free-of-charge mammography (ages 40 to 69) and mobile screening systems in recent years, a significant portion of patients were diagnosed at advanced stage due to lack of breast cancer awareness. In contrast with the study published 5 years ago, there was a decrease in the rate of pre-menopausal women and an increase in the breast conserving surgery.
{"title":"Breast Cancer in Turkey; An Analysis of 20.000 Patients with Breast Cancer.","authors":"V. Özmen, Tolga Özmen, V. Doğru","doi":"10.5152/ejbh.2019.4890","DOIUrl":"https://doi.org/10.5152/ejbh.2019.4890","url":null,"abstract":"Objective\u0000Breast cancer is the most common type of cancer and the leading cause of cancer-related deaths in women in Turkey. This study presents the characteristics of patients registered in National Breast Cancer Registry Program of Turkish Federation of Breast Diseases Societies.\u0000\u0000\u0000Materials and Methods\u0000The registry contains 242 variables under 10 categories and 699 questions. Patients were recorded (online and offline) from nationwide breast centers around Turkey.\u0000\u0000\u0000Results\u0000Twenty-thousand patients were registered between May 2005 and April 2017 at 36 centers. After data cleaning, 19,503 women were included in the study. The median age at diagnosis was 51 [14-97]; 17.2% were younger than 40 and 37.2% were premenopausal; 13.6% were nulliparous. Breast conserving surgery rate was 39.3%. Histopathology was invasive ductal cancer in 77%. Majority of patients had stage II cancer (48.3%). Estrogen, progesterone and HER-2 receptor positivity rates in invasive breast cancer were 72.5%, 62.5% and 21.8%, respectively. The mean tumor diameter was 2.5±1.7 cm. During the mean 51.6 months of follow-up, the local/regional and systemic recurrence rates were 3.7% and 5.2%, respectively; five and 10-year overall survival rates were 86% and 76%.\u0000\u0000\u0000Conclusion\u0000Despite increasing number of screening centers and free-of-charge mammography (ages 40 to 69) and mobile screening systems in recent years, a significant portion of patients were diagnosed at advanced stage due to lack of breast cancer awareness. In contrast with the study published 5 years ago, there was a decrease in the rate of pre-menopausal women and an increase in the breast conserving surgery.","PeriodicalId":91975,"journal":{"name":"The journal of breast health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43108090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
T. Duymaz, Z. E. İyigün, A. S. İlgün, Ç. Ordu, M. Üçüncü, G. Alço, Alper Öztürk, Filiz Elbüken, F. Aktepe, V. Özmen
Objective The aim of this study is to investigate the effect of mini latissimus dorsi flap (MLDF) reconstruction on ipsilateral shoulder functions. Materials and Methods Those included in the study are the patients aged between 23 and 73, who were operated with the diagnosis of early breast cancer (cT1-3)N0). The first group includes the patients who had sentinel lymph node biopsy (SLNB) with partial mastectomy. The second group consists of the patients who had axillary lymph nodule dissection (ALND) with partial mastectomy. The third group includes the patients who had SLNB and MLDF with partial mastectomy. The fourth group includes the patients who had ALND and MLDF with partial mastectomy. Patients' Quick Disabilities of the Arm, Shoulder and Hand (Q-DASH) score work model point were recorded. Results 174 patients were included in this study. According to Q-DASH score, no functional change was detected in 69.5% of the patients, whereas slight functional loss was identified in 23.6%, moderate functional loss in 5.7%, severe functional loss 1.1%. In the comparison of Q-DASH scores in surgery groups, while these four groups were being analyzed, a significant difference was determined (p=0.007). When dual analyses were made, it was also established that the difference resulted from the group to which ALND and MLDF were applied together. Conclusion We conclude that MLDF application for reconstruction purposes after breast surgery has a negative impact on shoulder functions of the patients who had both of partial mastectomy and ALND.
{"title":"The Effect of Mini-Latissimus Dorsi Flap (MLDF) Reconstruction on Shoulder Function in Breast Cancer Patients.","authors":"T. Duymaz, Z. E. İyigün, A. S. İlgün, Ç. Ordu, M. Üçüncü, G. Alço, Alper Öztürk, Filiz Elbüken, F. Aktepe, V. Özmen","doi":"10.5152/ejbh.2019.4727","DOIUrl":"https://doi.org/10.5152/ejbh.2019.4727","url":null,"abstract":"Objective\u0000The aim of this study is to investigate the effect of mini latissimus dorsi flap (MLDF) reconstruction on ipsilateral shoulder functions.\u0000\u0000\u0000Materials and Methods\u0000Those included in the study are the patients aged between 23 and 73, who were operated with the diagnosis of early breast cancer (cT1-3)N0). The first group includes the patients who had sentinel lymph node biopsy (SLNB) with partial mastectomy. The second group consists of the patients who had axillary lymph nodule dissection (ALND) with partial mastectomy. The third group includes the patients who had SLNB and MLDF with partial mastectomy. The fourth group includes the patients who had ALND and MLDF with partial mastectomy. Patients' Quick Disabilities of the Arm, Shoulder and Hand (Q-DASH) score work model point were recorded.\u0000\u0000\u0000Results\u0000174 patients were included in this study. According to Q-DASH score, no functional change was detected in 69.5% of the patients, whereas slight functional loss was identified in 23.6%, moderate functional loss in 5.7%, severe functional loss 1.1%. In the comparison of Q-DASH scores in surgery groups, while these four groups were being analyzed, a significant difference was determined (p=0.007). When dual analyses were made, it was also established that the difference resulted from the group to which ALND and MLDF were applied together.\u0000\u0000\u0000Conclusion\u0000We conclude that MLDF application for reconstruction purposes after breast surgery has a negative impact on shoulder functions of the patients who had both of partial mastectomy and ALND.","PeriodicalId":91975,"journal":{"name":"The journal of breast health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47044755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective To determine the influence of the Oncotype Dx assay on the treatment of patients with Estrogen Receptor (ER)-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative, axillary lymph node-negative or micrometastatic carcinoma of the breast in a single cancer center. In addition, patients with intermediate Oncotype Dx recurrence scores were analyzed to assess the factors influencing therapeutic decisions for adjuvant chemotherapy. Materials and Methods Data from medical records of women diagnosed with carcinoma of the breast and qualified for the Oncotype Dx assay were extracted (OncoDx cohort). Patient demographic and cancer characteristics, genomic report, and course of treatment data, including survival outcomes and treatment decision-making, were analyzed. A matched cohort of patients with similar tumor stage and biology (ER-positive, HER2-negative) from the era before the introduction of the Oncotype Dx assay was analyzed for comparison (pre-OncoDx cohort). Results Two hundred and one patients were included in the OncoDx cohort and one hundred and sixty patients were included in the pre-OncoDx cohort. Oncotype Dx recurrence score (RS) was low (<11) in fifty-six patients (28%), intermediate (11-25) in one hundred and twenty-three patients (61.5%) and high (>25) in twenty one patients (10.5%). Demographic and cancer clinicopathologic characteristics between OncoDx and pre-OncoDx cohorts were similar. Overall, 10.9% of the patients in the OncoDx cohort received adjuvant chemotherapy, versus 23.8% of the patients in the pre-OncoDx cohort (Fisher exact p=0.003). Fewer patients were recommended adjuvant chemotherapy in the OncoDx era compared to the pre-OncoDx era (17.9% vs 30.6%, respectively, Fisher exact p=0.006). The decision to recommend chemotherapy within the intermediate-risk cohort was influenced by the patient's RS. The mean RS of patients in the intermediate-risk cohort who did not receive chemotherapy was 21.5 while the score of those that received chemotherapy was 24.6 (p=0.000). The series confirmed excellent PFS and OS for both OncoDx and pre-OncoDx cohorts. Conclusion This single cancer center analysis confirms the avoidance of chemotherapy in the great majority of patients with early ER-positive, HER2-negative, lymph node-negative or micrometastatic carcinoma of the breast since the introduction of the Oncotype Dx assay. A higher recurrence risk score within the intermediate group may influence the decision for chemotherapy inclusion in the adjuvant treatment plan. A lower PR percentage by IHC and higher grade may predict higher Oncotype Dx scores.
{"title":"The Oncotype Dx Assay in ER-Positive, HER2-Negative Breast Cancer Patients: A Real Life Experience from a Single Cancer Center.","authors":"S. Thibodeau, I. Voutsadakis","doi":"10.5152/ejbh.2019.4901","DOIUrl":"https://doi.org/10.5152/ejbh.2019.4901","url":null,"abstract":"Objective\u0000To determine the influence of the Oncotype Dx assay on the treatment of patients with Estrogen Receptor (ER)-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative, axillary lymph node-negative or micrometastatic carcinoma of the breast in a single cancer center. In addition, patients with intermediate Oncotype Dx recurrence scores were analyzed to assess the factors influencing therapeutic decisions for adjuvant chemotherapy.\u0000\u0000\u0000Materials and Methods\u0000Data from medical records of women diagnosed with carcinoma of the breast and qualified for the Oncotype Dx assay were extracted (OncoDx cohort). Patient demographic and cancer characteristics, genomic report, and course of treatment data, including survival outcomes and treatment decision-making, were analyzed. A matched cohort of patients with similar tumor stage and biology (ER-positive, HER2-negative) from the era before the introduction of the Oncotype Dx assay was analyzed for comparison (pre-OncoDx cohort).\u0000\u0000\u0000Results\u0000Two hundred and one patients were included in the OncoDx cohort and one hundred and sixty patients were included in the pre-OncoDx cohort. Oncotype Dx recurrence score (RS) was low (<11) in fifty-six patients (28%), intermediate (11-25) in one hundred and twenty-three patients (61.5%) and high (>25) in twenty one patients (10.5%). Demographic and cancer clinicopathologic characteristics between OncoDx and pre-OncoDx cohorts were similar. Overall, 10.9% of the patients in the OncoDx cohort received adjuvant chemotherapy, versus 23.8% of the patients in the pre-OncoDx cohort (Fisher exact p=0.003). Fewer patients were recommended adjuvant chemotherapy in the OncoDx era compared to the pre-OncoDx era (17.9% vs 30.6%, respectively, Fisher exact p=0.006). The decision to recommend chemotherapy within the intermediate-risk cohort was influenced by the patient's RS. The mean RS of patients in the intermediate-risk cohort who did not receive chemotherapy was 21.5 while the score of those that received chemotherapy was 24.6 (p=0.000). The series confirmed excellent PFS and OS for both OncoDx and pre-OncoDx cohorts.\u0000\u0000\u0000Conclusion\u0000This single cancer center analysis confirms the avoidance of chemotherapy in the great majority of patients with early ER-positive, HER2-negative, lymph node-negative or micrometastatic carcinoma of the breast since the introduction of the Oncotype Dx assay. A higher recurrence risk score within the intermediate group may influence the decision for chemotherapy inclusion in the adjuvant treatment plan. A lower PR percentage by IHC and higher grade may predict higher Oncotype Dx scores.","PeriodicalId":91975,"journal":{"name":"The journal of breast health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48052025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：